SCHEDULE: Deep Track Capital Discloses 8.46% Stake in Tarsus Pharmaceuticals

Deep Track Capital, LP, along with its affiliates, has reported beneficial ownership of 3,600,000 shares, representing 8.46% of the outstanding common stock of Tarsus Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin have jointly filed a Schedule 13G, indicating their beneficial ownership of Tarsus Pharmaceuticals, Inc. common stock.
• As of March 31, 2026, the reporting persons collectively beneficially own 3,600,000 shares of Tarsus Pharmaceuticals, Inc. common stock.
• This holding represents 8.46% of the class of securities outstanding.
• The filing indicates shared voting and dispositive power over these shares.
• David Kroin is identified as a control person for Deep Track Capital, LP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not contain operational or financial performance updates.

Positives

• Significant ownership stake of 8.46% in Tarsus Pharmaceuticals, Inc. by Deep Track Capital and its affiliates.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard disclosures associated with a Schedule 13G filing.

Future Outlook

This filing is a Schedule 13G, which primarily reports beneficial ownership and does not typically contain forward-looking statements or company guidance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates Deep Track Capital's substantial investment in Tarsus Pharmaceuticals, Inc., a move that could signal confidence in the company's future prospects or a strategic investment for potential influence.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Management of Tarsus Pharmaceuticals, Inc.: Awareness of a substantial institutional investor's position, which may lead to engagement on corporate strategy or governance.

Next Steps

• Continued monitoring of Tarsus Pharmaceuticals, Inc. for any further filings or announcements from Deep Track Capital, LP.

Key Dates

Recommendation

This filing is a disclosure of beneficial ownership and does not provide information on the company's financial performance, strategic direction, or future outlook. Therefore, a 'hold' recommendation is appropriate, suggesting investors maintain their current positions pending further material information.

Keywords

Tarsus Pharmaceuticals, Schedule 13G, Deep Track Capital, Beneficial Ownership, SEC Filing, Investment, Common Stock, Shareholder